After One Dose of Gene Therapy, Hemophilia B Patients Maintain Near-Normal Levels of Clotting Factor Saturday, December 03, 2016 SAN DIEGO ,... ...https://www.asianhhm.com/pressreleases/after-one-dose-of-gene-therapy-hemophilia-b-patients-maintain-near-normal-levels-of-clotting-factor
Saturday, December 03, 2016 SAN DIEGO , Dec. 3, 2016 /PRNewswire-USNewswire/ --In five studies being presented today during the 58th American... ...https://www.pharmafocusasia.com/pressreleases/bioengineering-innovations-show-promise-for-improving-treatments-and-drug-delivery
Saturday, December 03, 2016 SAN DIEGO , Dec. 3, 2016 /PRNewswire-USNewswire/ -- Sickle cell disease (SCD) is an inherited chronic disorder... ...https://www.pharmafocusasia.com/pressreleases/sickle-cell-disease-research-shows-progress-in-preventing-related-complications-and-death
Washington D.C [US], Dec. 4 (ANI): In a recent research presented at the 58th ASH Annual Meeting, scientists have reported the highest and most... ...https://in.news.yahoo.com/scientists-discover-essential-blood-clotting-factors-hemophilia-b-052903435.html
CTL019 is part of an experimental class of drugs that are made by genetically altering a patient's T-cells, a type of white blood cell, in the lab... ...http://indianexpress.com/article/lifestyle/health/novartis-says-82-pct-of-leukemia-patients-in-remission-after-car-t-4409538/
An additional reason precisely why...